Tag: GLP-1
Weight loss drugs help with fat loss – but they cause bone and muscle loss too
GLP-1-based drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) work by helping people to feel less hungry. This results in them eating less – leading to weight loss.
Studies show that these drugs are very effective in helping people lose weight. In clinical trials of people with obesity, these drugs lead to a weight loss of up to 20% body weight in some instances.
But it’s important to note that not all the weight lost is fat. Research shows that up to one-third of this weight loss is so-called “non-fat mass” – this includes muscle and bone mass.
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Dry industry officials estimate that several large compounding pharmacies are provisioning up to 2 million American patients with regular doses of semaglutide, the scientific name for Novo Nordisk’s Wegovy, Ozempic, and Rybelsus formulations, or tirzepatide, the active ingredient in Eli Lilly’s Zepbound and Mounjaro.
As Zepbound dominates headlines as a new obesity-fighting drug, a nutritionist warns that weight loss shouldn’t be the only goal
Weight loss medications are intended to be used in conjunction with lifestyle changes, such as exercise and a healthy diet. But too often, people view them as a silver bullet for weight loss. And the high price tag and variable insurance coverage for these popular weight loss drugs create a barrier for many people.